Opening Recap
Market Pulse: Chip stocks raced ahead yesterday, pulling the tech sector into overdrive as earnings surprises piled up across semiconductors and software providers.
Key Movers: “Intel Stock Jumps On Chipmaker's Big Q2 Earnings Beat” and “SAP shrugs off AI eating software fears with big earnings beat” grabbed headlines, while Cleveland-Cliffs stunned markets with a hefty defense contract.
Macro & Politics: Mukesh Ambani’s three-year spending binge is set to flip into nearly Rs 90,000 crore of free cash flow, spotlighting India’s industrial powerhouse—and stirring investor FOMO globally.
What’s Next: Look for the next wave of earnings reports to test this momentum and set the tone before the weekend.
Market Commentary
People are cheering the surge in chip bellwethers after “Intel Stock Jumps On Chipmaker's Big Q2 Earnings Beat” (Slashdot.org), but few are calling out how mounting supply-chain snags could pinch margins in the back half. When you’re banking on another tech bull run, missing that detail is a recipe for a rude shock.
Here’s the curveball: SAP’s resilience on AI fears (SiliconANGLE News) and Cleveland-Cliffs beating estimates plus landing a $400M defense deal (Ibtimes.com.au) tell the same story—legacy giants aren’t going quietly. From enterprise software to steelmakers, incumbents are flipping the script and crusting skeptics, proving that sometimes the tried-and-true still pack a punch.
Your move: shift a slice of capital toward those stalwarts demonstrating real grit, but don’t get sucked into headline hysteria on unproven biotech plays like those peptides (Wired). Stay alert, weigh your risks, and keep some dry powder for the next mispriced opportunity.
📈 Breaking Financial News
Intel Stock Jumps On Chipmaker's Big Q2 Earnings Beat – Investor's Business Daily
Intel's stock jumps as chipmaker rides AI boom to fastest revenue growth in almost 15 years. Investor's Business Daily reports that Intel smashed expectations, sending chip bulls into overdrive.
SAP shrugs off AI eating software fears with big earnings beat
Enterprise software giant SAP SE shook off concerns that AI would cannibalize its legacy business by posting solid results in its latest earnings report, turning skeptics into believers.
Intel Stock Jumps On Chipmaker's Big Q2 Earnings Beat
Intel smashed Wall Street's targets for Q2 and guided well for Q3. The post appeared first on Investor's Business Daily, highlighting the chipmaker's robust performance.
These Industrial Stock Moves Send A Bullish Signal About The Economy
A coordinated beat-and-raise from top XLI ETF holdings suggests an industrial upswing, hinting at stronger cap-ex and profit margins ahead.
There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders
Eli Lilly delayed filing for FDA approval of its next-gen weight-loss drug retatrutide until Q1, revealing hidden value dynamics and potential pressure on compounders.
Something doesn't add up.
Jobs that “existed”… didn't in reality. The government deploying record AI spending. Yet Buffett holds $344B cash—his largest position EVER. Louis Navellier's grading system reveals what the Wall Street elite see but won't tell you.
🔍 Market Analysis & Insights
Mukesh Ambani’s long game: How Reliance could turn a 3-year spending spree into Rs 90,000 crore of free cash flow
Reliance Industries could generate nearly Rs 90,000 crore in cumulative free cash flow over FY26–FY28 as investments ease, powered by stronger earnings from energy and Jio.
An FDA Panel Just Endorsed These Unproven Peptides
Outside experts, some with vested interests, recommended adding peptides like the “Wolverine stack” to the FDA's bulk list. Caveat emptor applies if you're eyeing a swing trade.
The World's First CRISPR Gene Therapy Just Got Approved for Children as Young as 2 with Sickle Cell Disease
The FDA expanded Casgevy CRISPR therapy to children as young as 2. Families should review eligibility and access details amid this groundbreaking approval.
Hoka Leads Deckers’ $1B First Quarter Performance After Earnings Beat
Deckers Brands saw Q1 net sales rise 5.7% to $1.02 billion, driven by strong Hoka performance and consumer appetite for premium footwear.
Own VAS ETF? Here's how your investment performed in FY26
VAS, the most popular ETF with $25.37 billion under management, saw notable returns in FY26. The Motley Fool Australia details the performance metrics.
The Comeback of the Century: Wall Street Wrote Him Off…
But Elon's $3 Trillion Comeback Could Begin Soon. Elon Musk was declared washed up and finished. But any day now, he could unveil a new technology that outshines Tesla, SpaceX, even PayPal… Details here.
💰 Investment Opportunities
FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
An FDA advisory committee voted to include BPC-157 on a drug compounding list, opening potential—but risky—biotech avenues for speculative traders.
Cleveland-Cliffs Stock Jumps 20% as Steel Maker Beats Estimates and Lands New $400 Million Defense Deal
Cleveland-Cliffs shares surged 20% after surpassing earnings expectations and securing a $400 million defense contract, signaling a stealth industrial recovery.
Morgan Stanley doubles down on Schwab after earnings
Charles Schwab delivered one of its strongest quarters, and Morgan Stanley is taking notice, suggesting growing confidence in the brokerage's wealth-management trajectory.
A Mag 7 Peer Just Directed The Market to Load Up on Amazon Before July 30
A Mag 7 giant's cloud earnings report has quietly flashed a buy signal for Amazon, highlighting a potential short-squeeze setup ahead of month-end.
The Comeback of the Century: Wall Street Wrote Him Off…
But Elon's $3 Trillion Comeback Could Begin Soon. Elon Musk was declared washed up and finished. But any day now, he could unveil a new technology that outshines Tesla, SpaceX, even PayPal… Details here.